Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 1 AL 15

Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?

Borger E, Aitken L, Du H, Zhang W, Gunn-Moore FJ, Yan SS.

Curr Alzheimer Res. 2013 Jan;10(1):21-9.

Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease

Motel WC, Coop A, Cunningham CW.

Mini Rev Med Chem. 2013 Mar;13(3):456-66. doi: 10.2174/138955713804999784.

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study

del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, León T.

J Alzheimers Dis. 2013;33(1):205-15. doi: 10.3233/JAD-2012-120805.

The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease

Lewis JE, McDaniel HR, Agronin ME, Loewenstein DA, Riveros J, Mestre R, Martinez M, Colina N, Abreu D, Konefal J, Woolger JM, Ali KH.

J Alzheimers Dis. 2013;33(2):393-406. doi: 10.3233/JAD-2012-121381.

Molecular mechanism aspect of ER stress in Alzheimer's disease: current approaches and future strategies

Ansari N, Khodagholi F.

Curr Drug Targets. 2013 Jan 1;14(1):114-22. doi: 10.2174/138945013804806532.

Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers

Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S.

Br J Clin Pharmacol. 2013 May;75(5):1299-311. doi: 10.1111/j.1365-2125.2012.04472.x.

A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease

Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E.

Br J Clin Pharmacol. 2013 May;75(5):1231-9. doi: 10.1111/bcp.12018.

Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure

de Aquino RA, Modolo LV, Alves RB, de Fatima A.

Curr Drug Targets. 2013 Mar;14(3):378-97. doi: 10.2174/138945013804999043.

β-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: a new paradigm for prognosis and therapy?

Femminella GD, Rengo G, Pagano G, de Lucia C, Komici K, Parisi V, Cannavo A, Liccardo D, Vigorito C, Filardi PP, Ferrara N, Leosco D.

J Alzheimers Dis. 2013;34(2):341-7. doi: 10.3233/JAD-121813.

Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU

Lyseng-Williamson KA, McKeage K.

Drugs Aging. 2013 Jan;30(1):51-8. doi: 10.1007/s40266-012-0041-0.

A comparison of psychosocial outcomes in elderly Alzheimer caregivers and noncaregivers

Mausbach BT, Chattillion EA, Roepke SK, Patterson TL, Grant I.

Am J Geriatr Psychiatry. 2013 Jan;21(1):5-13. doi: 10.1016/j.jagp.2012.10.001. Epub 2013 Jan 2.

Proteoglycans in the central nervous system: role in development, neural repair, and Alzheimer's disease

Cui H, Freeman C, Jacobson GA, Small DH.

IUBMB Life. 2013 Feb;65(2):108-20. doi: 10.1002/iub.1118. Epub 2013 Jan 7.

Current progresses of novel natural products and their derivatives/ analogs as anti-Alzheimer candidates: an update

Fang L, Gou S, Fang X, Cheng L, Fleck C.

Mini Rev Med Chem. 2013 May 1;13(6):870-87. doi: 10.2174/1389557511313060009.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias